May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Intravitreal Bevacizumab in the Treatment of Macular Edema - A Interventional Pilot Study
Author Affiliations & Notes
  • S. Petroni
    Inst Ophthalmology, Catholic University, Rome, Italy
  • A. M. Minnella
    Inst Ophthalmology, Catholic University, Rome, Italy
  • A. Scupola
    Inst Ophthalmology, Catholic University, Rome, Italy
  • L. Ziccardi
    Inst Ophthalmology, Catholic University, Rome, Italy
  • M. C. Savastano
    Inst Ophthalmology, Catholic University, Rome, Italy
  • P. Sasso
    Inst Ophthalmology, Catholic University, Rome, Italy
  • G. Stifano
    Inst Ophthalmology, Catholic University, Rome, Italy
  • G. Zinzanella
    Inst Ophthalmology, Catholic University, Rome, Italy
  • D. Marangoni
    Inst Ophthalmology, Catholic University, Rome, Italy
  • E. Balestrazzi
    Inst Ophthalmology, Catholic University, Rome, Italy
  • Footnotes
    Commercial Relationships S. Petroni, None; A.M. Minnella, None; A. Scupola, None; L. Ziccardi, None; M.C. Savastano, None; P. Sasso, None; G. Stifano, None; G. Zinzanella, None; D. Marangoni, None; E. Balestrazzi, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 1418. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. Petroni, A. M. Minnella, A. Scupola, L. Ziccardi, M. C. Savastano, P. Sasso, G. Stifano, G. Zinzanella, D. Marangoni, E. Balestrazzi; Intravitreal Bevacizumab in the Treatment of Macular Edema - A Interventional Pilot Study. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1418.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To evaluate the efficacy and safety of intravitreal injections of bevacizumab in diabetic and vascular (following central or branch vein occlusion) macular edema

Methods:: This case series study included 15 eyes of patients with diabetic (n=9, mean age 62,3; DS 8,1) and vascular (n= mean age 53,2 DS 15,7) macular edema refractory to conventional therapy. All eyes were treated with intravitreal injections of bevacizumab (0,05ml, 1,25 mg), with a mean of 2 retreatments, and longitudinally evaluated before and after the treatment by serial clinical, OCT and FERG measurements, as well as fluorescein angiography, over a six month period. Macular retinal thickness was determined by the standard OCT 3 Stratus algorithm. FERGs were recorded in response to an 18 degrees flickering stimulus modulated sinusoidally at 41 Hz. Response amplitude and phase were monitored. The fellow uninjected eyes of patients served as control.

Results:: Compared to baseline, mean retinal thickness, mean FERG amplitude and visual acuity significantly improved at 15 day from the injection in both groups, and gradually started to worsen at the end of follow-up (six months) in diabetic macular edema group of patients with a mean gain of 2 ETDRS letters and a mean reduction of 39 micron foveal macular thickness. In patients with vascular macular edema we found at six month follow-up a stabilization of the same parameters compared to baseline, with an mean gain of 8 ETDRS letter and a mean gain of 167 microns foveal macular thickness.

Conclusions:: Results indicate that intravitreal bevacizumab induces short-term beneficial changes in both macular structure and function in eyes with diabetic and vascular macular edema, and suggest that this treatment is avoid of toxic effects on the outer neural retina. Six month follow up data indicate a good response only in vascular macular edema but not in diabetic macular edema

Keywords: diabetic retinopathy • drug toxicity/drug effects • imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound) 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×